SCHEMBL6906186

SCHEMBL6906186

CCCCOC(=O)NC(C)C(=O)N1CCCC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.47
HRH2 P25021 2/20 0.45
HRH1 P35367 2/20 0.45
SMN1; SMN2 Q16637 4/20 0.44
KMT2A Q03164 2/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
TP53 P04637 1/20 0.44
MAPT P10636 1/20 0.44
NFKB1 P19838 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44
HPGD P15428 3/20 0.40
MEN1 O00255 1/20 0.40
LMNA P02545 1/20 0.40
POLB P06746 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
ACE P12821 1/20 0.39
ACE2 Q9BYF1 1/20 0.39
EPHX1 P07099 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL524090 0.79 HRH2 (0.55) HRH2HRH1SMN1; SMN2MAPTLMNA
SCHEMBL524089 0.79 HRH2 (0.55) HRH2HRH1SMN1; SMN2MAPTLMNA
SCHEMBL8382659 0.77 EPHX1 (0.52) ALDH1A1SMN1; SMN2KMT2ANPC1RAB9A
SCHEMBL20434056 0.77 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2KMT2ANPC1RAB9A
SCHEMBL476725 0.76 EPHX1 (0.47) ALDH1A1SMN1; SMN2NPC1RAB9AHPGD
SCHEMBL459574 0.76 EPHX1 (0.47) ALDH1A1SMN1; SMN2NPC1RAB9AHPGD
SCHEMBL459573 0.76 EPHX1 (0.47) ALDH1A1SMN1; SMN2NPC1RAB9AHPGD
SCHEMBL6505996 0.76 TSHR (0.47) ALDH1A1SMN1; SMN2NPC1RAB9AMAPT
Hydrochloric Acid SCHEMBL10476064 0.74 EPHX1 (0.46) ALDH1A1SMN1; SMN2NPC1RAB9AHPGD
SCHEMBL7771457 0.74 EPHX1 (0.46) ALDH1A1SMN1; SMN2NPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040023975-A1 Pharmaceutical compositions for the treatment of systemic inflammatory response syndrome BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040023975-A1 Pharmaceutical compositions for the treatment of systemic inflammatory response syndrome IL5, TSLP, TLR5 ALDH1A1 1668/4885HRH2 77/4885HRH1 227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.